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Within tumors, some areas are less oxygenated than others. Since their home ground 
is under chronic hypoxia, tumor cells adapt to this condition by activating aerobic gly-
colysis; however, this hypoxic environment is very harsh for incoming immune cells. 
Deprivation of oxygen limits availability of energy sources and induces accumulation 
of extracellular adenosine in tumors. Extracellular adenosine, upon binding with ade-
nosine receptors on the surface of various immune cells, suppresses pro-inflammatory 
activities. In addition, signaling through adenosine receptors upregulates a number of 
anti-inflammatory molecules and immunoregulatory cells, leading to the establishment 
of a long-lasting immunosuppressive environment. Thus, due to hypoxia and adenosine, 
tumors can discourage antitumor immune responses no matter how the response was 
induced, whether it was spontaneous or artificially introduced with a therapeutic intention. 
Preclinical studies have shown the significance of adenosine in tumor survival strategy 
by demonstrating tumor regression after inactivation of adenosine receptors, inhibition 
of adenosine-producing enzymes, or reversal of tissue hypoxia. These promising results 
indicate a potential use of the inhibitors of the hypoxia–adenosine pathway for cancer 
immunotherapy.
Keywords: adenosine, tumor microenvironment, A2A adenosine receptor, CD73, tissue hypoxia, 
immunosuppression, immune checkpoint, cancer immunotherapy
iMMUNe CHeCKPOiNT
The discovery of tumor-associated antigens and tumor-reactive immune cells led to a promise of 
a new cancer therapy based on tumor antigen-specific immune responses. Preventing successful 
immunotherapy of cancer is the immunosuppressive nature of the tumor microenvironment (1–3). 
In animals expressing the same antigen in both tumors and normal tissue, the intensity of antigen-
specific T cell response was diminished in tumors, while the same T cells were vigorously activated 
in normal tissue (4, 5). T cells infiltrated in tumor tissue are often capable of recognizing tumor-
associated antigen, but they coexist with their target, tumor cells, without significant antitumor 
activity. However, when isolated from tumor tissue, those tumor-infiltrated T cells could kill the 
tumor cells efficiently in vitro (6). These studies indicate that tumors establish a stern environment 
for antitumor immune cells, cells that can be active effector cells otherwise.
Many of the immunosuppressive mechanisms in tumors are common to physiological immu-
noregulation in normal tissues. Such immunoregulation is very important in keeping the immune 
system under control in order to block a self-reactive immune response and to prevent an ongoing 
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immune response from causing critical tissue damage. The lack of 
physiological immunoregulation often results in overwhelming 
immune activation that accompanies autoimmunity. For exam-
ple, CTLA-4 is a physiological mechanism that negatively regu-
lates T cell activity by blocking a costimulatory signal through 
CD28–B7 interaction. The lack of CTLA-4 causes non-specific 
T cell activation, and CTLA-4-deficient mice die in several weeks 
with massive lymphocytic tissue infiltration (7, 8). In humans, 
heterozygous mutation in the CTLA-4 gene is enough to cause 
immune dysregulation similar to homozygous  CTLA-4-knockout 
mice (9). PD-1 also provides a T cell inhibitory signal upon inter-
action with its ligands, PD-L1 and PD-L2. Deficiency of PD-1 in 
mice is known to cause various types of autoimmune disorders 
depending on the genetic strains (10).
Besides cell surface transducers of immunosuppressive 
signal, e.g., CTLA-4 and PD-1, immunosuppression in the 
tumor microenvironment involves anti-inflammatory cytokines 
(IL-10,  TGF-β), enzymes (indoleamine-2,3-dioxygenase), 
and professional immunoregulatory cells [regulatory T cells, 
myeloid-derived suppressor cells (MDSCs)] (1, 2). These immu-
nosuppressive mechanisms play an important role in controlling 
immune response in normal tissues, not tumor tissue specific. 
Since tumors take advantage of such physiological immunoregu-
latory mechanisms to protect their tissue from immune attack, 
these mechanisms intended to prevent inflammatory complica-
tion, now turn out to be major obstacles hampering spontaneous 
cancer regression and immunological cancer treatment. The 
identification of immunosuppressive mechanisms in tumors 
pointed out molecular targets to restore the antitumor immune 
response. Thus, these negative immunoregulatory mechanisms, 
so-called immune checkpoints, became a focus in drug discovery. 
The effort resulted in FDA approval of anti-CTLA-4 and anti-
PD-1 antibodies for cancer treatment. This achievement finally 
convinced people that immunotherapy of cancer is realistic, and 
it further encouraged the development of inhibitors of other 
immune checkpoint molecules (10–12).
Extracellular adenosine has been known as an inhibitor of 
immune functions. While intracellular adenosine is involved 
in energy metabolism, nucleic acid metabolism, and the 
methionine cycle, extracellular adenosine plays an important 
role in intercellular signaling. Its signal is transmitted by 
G protein-coupled adenosine receptors on the cell surface, 
and it affects diverse physiological functions including 
neurological, cardiovascular, and immunological systems 
(13). Extracellular concentration of adenosine can increase 
in response to metabolic change. When cells are deprived of 
nutrients or oxygen, insufficient ATP biosynthesis tends to 
lower the ATP/adenosine ratio. To reduce ATP expenditure, 
cells may suspend energy-consuming activities such as cell 
proliferation, which requires biosynthesis of a large amount of 
cellular components (14, 15). Indeed, tissue hypoxia strongly 
represses proliferation of activated T cells (16). Interestingly, 
extracellular adenosine is known to accumulate under hypoxic 
conditions. Adenosine signaling may play a role in the improve-
ment of energy status by promoting catabolism of stored 
metabolic energy. Correspondingly, extracellular adenosine 
increases energy expenditure through the induction of lipolysis 
(17). Tumors contain high levels of extracellular adenosine (18, 
19),  suggesting that tumor cells may benefit from its immu-
nosuppressive effect and catabolic energy production. The 
current review focuses on the  pro-cancer roles of extracellular 
adenosine and discusses application of the inhibitors of this 
metabolic immune checkpoint to cancer immunotherapy.
ADeNOSiNe ReCePTORS AND 
SUPPReSSiON OF ANTiTUMOR 
iMMUNiTY
Of the four known types of adenosine receptors, A2A adenosine 
receptor (A2AR) is the predominantly expressed subtype in 
most immune cells (13). Stimulation of A2AR generally provides 
an immunosuppressive signal that inhibits activities of T cells 
(proliferation, cytokine production, cytotoxicity), NK cells 
(cytotoxicity), NKT cells (cytokine production, CD40L upregu-
lation), macrophages/dendritic cells (antigen presentation, 
cytokine production), and neutrophils (oxidative burst) (20, 21). 
Administration of A2AR agonist strongly inhibits induction of 
various inflammatory diseases (22, 23). Endogenous adenosine 
shows similar immunoregulatory activity via A2AR, and this 
mechanism is critical to the control of the immune response. 
Exaggeration of inflammatory tissue injury in A2AR-deficient 
mice indicated that no other immunoregulatory mechanism 
could compensate for the lack of the adenosine-dependent 
immunoregulation (20, 24–28).
In 2006, the presence of high levels of extracellular adenosine 
in tumors was found to play a significant role in the evasion of 
antitumor immune response (19). The study showed that A2AR-
deficient mice could spontaneously regress the inoculated tumor, 
whereas no wild-type mice showed similar tumor regression. 
A2AR antagonists were also beneficial in tumor-bearing wild-type 
animals. Importantly, depletion of T cells and NK cells impaired 
the retardation of tumor growth by A2AR antagonists, suggesting 
improvement of antitumor cellular immune response (19, 29). 
Effector functions of T cells and NK cells are susceptible to A2AR 
stimulation. In addition, when activated in the presence of A2AR 
agonist, the effector function of T cells is persistently impaired 
even after removal of A2AR agonist (30, 31). This result suggests 
that the adenosine-rich environment in tumors may induce T cells 
that are anergic to the tumor cells. Consistent with this change, 
A2AR stimulation induces immunoregulatory molecules such as 
CTLA-4 and PD-1 on T cells (32–34). Antigen-presenting cells 
(APCs) are also targets of adenosine. A2AR agonists suppress 
IL-12 and induce IL-10 production from APCs, discouraging 
cellular immune response (35, 36). Conversely, myeloid-specific 
deletion of A2AR enhanced tumor infiltration of effector T cells 
and NK cells (37). These studies show A2AR-dependent sup-
pression of antitumor T cell activity. However, a recent study 
reported an interesting finding that A2AR-deficient antitumor 
T cells might have a shorter half-life in vivo (38). A2AR-deficient 
T cells effectively elicit antitumor activities in the adenosine-rich 
tumor microenvironment, but if these cells were to disappear 
prematurely, they may not complete tumor regression and may 
actually result in tumor regrowth. Further studies with this issue 
TABLe 1 | Representative A2AR/A2BR antagonists (majority of A2AR 
antagonists were developed for Parkinson’s disease; *under cancer 
clinical trial).
A2AR A2BR
Clinical CPI-444* CVT-6883
PBF-509*
Istradefylline (KW-6002)
Preladenant (SCH420814)
Tozadenant (SYN115)
Vipadenant (BIIB014)
HTL-1071
ST1535
Others SCH412348 MRE2029F20
SCH442416 MRS1754
SCH58261 PSB603
ZM241385
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may result in an improved  treatment in which adenosine-resistant 
antitumor effector cells can offer persistent immune response.
Furthermore, adenosine recruits immunoregulatory activity 
of regulatory T (Treg) cells. FoxP3, a key transcriptional factor 
for the immunosuppressive activity of Treg cells, is inducible by 
A2AR stimulation (30). T cell activation in the presence of A2AR 
stimulation largely increases CD4+ FoxP3+ cells (33, 39–41). 
Interestingly, in addition to the numerical increase of Treg cells, 
A2AR stimulation augmented the immunoregulatory activity of 
Treg cells (33). Consistent with the increase in regulatory activity 
in vitro, Treg cell-dependent prevention of in vivo inflammatory 
disease induction could be enhanced by pretreating Treg cells 
with A2AR agonist before transfer (39). In contrast, transfer of 
A2AR-deficient Treg cells failed to save the tissue from inflamma-
tory damage (42), suggesting that endogenous adenosine may be 
important in the modulation of Treg activity in vivo.
A2B adenosine receptor (A2BR) can also potentially medi-
ate immunosuppressive activity of extracellular adenosine, but 
the mechanisms of A2BR-dependent immunosuppression are 
different from those of A2AR. A2BR-dependent immunoregu-
lation is notable in myeloid cells. A2BR plays a predominant 
role in the adenosine-dependent differentiation of macrophages 
into M2-type (43–45). Those macrophages activated in the 
presence of A2BR stimulation express arginase, indoleamine-
2,3-dioxygenase, and TGF-β, and have limited T cell stimula-
tory activity. In addition to the induction of such tolerogenic 
APCs, the adenosine–A2BR interaction results in the expansion 
of MDSCs (46). Indeed, treatment of tumor-bearing mice with 
A2BR agonist increased MDSC in tumors and accelerated 
tumor growth (47).
Immunoregulatory activity of A2BR is also involved in the 
suppression of antitumor immunity by adenosine present in the 
tumor microenvironment. Slower tumor growth was observed 
in A2BR-deficient mice and A2BR antagonist-treated wild-type 
mice (48, 49). Recruitment of T cell immunity was necessary 
to provoke antitumor effect of A2BR antagonist because the 
treatment was not effective in T cell-deficient animals (49). 
Diminished tumor growth by A2BR antagonist accompanied a 
greater number of T cell infiltration but reduced numbers of Treg 
cells and MDSC (47, 49, 50).
Thus, extracellular adenosine downregulates antitumor 
immune response in various ways. The mechanisms of immu-
nosuppression involve not only direct effects on antitumor 
effector cells but also indirect effects on APCs and professional 
immunoregulatory cells such as Treg cells and MDSC. A2AR 
and/or A2BR mediate immunosuppressive effects of adenosine 
depending on cell types. Interestingly, A2AR and A2BR seem to 
mainly target lymphoid cells and myeloid cells, respectively. The 
impact of adenosine-mediated immunosuppression seems to be 
persistent rather than transient because the outcome of adenosine 
exposure can induce M2-type tumor-associated macrophages, 
Treg cells, MDSC, and “anergic” effector T cells. These facts sup-
port an idea that extracellular adenosine is a negative immune 
checkpoint molecule that plays a significant role in establishing 
an immunosuppressive tumor microenvironment. Therefore, it is 
reasonable to target the adenosine-dependent pathway in order to 
improve cancer therapy. The blockade of A2AR and A2BR using 
antagonists has demonstrated promise for a new therapeutic 
approach (Table 1).
CANCeR iMMUNOTHeRAPY BY 
TARGeTiNG ADeNOSiNe-PRODUCiNG 
MeCHANiSM
To inactivate the adenosine-dependent immunosuppression, it 
would be beneficial to think about the metabolism of extracellular 
adenosine. The source of extracellular adenosine is believed to be 
ATP in the extracellular compartment. There are nucleotidases on 
the cell surface called CD39 and CD73. CD39 catalyzes hydrolysis 
of ATP/ADP to AMP, and CD73 converts AMP to adenosine. Very 
low extracellular adenosine levels in CD73-deficient mice suggest 
that degradation of ATP is a major source of extracellular adeno-
sine (51, 52). Adenosine is metabolized to inosine by adenosine 
deaminase or converted to AMP by the function of adenosine 
kinase. Tissue hypoxia can induce accumulation of extracellular 
adenosine by increasing adenosine production and by decreas-
ing adenosine removal. Hypoxia induces the mRNA levels and 
enzymatic activities of CD39 and CD73 leading to an increase in 
adenosine production (53, 54). The rate of adenosine removal can 
be reduced by hypoxia-dependent inhibition of adenosine kinase, 
resulting in further accumulation of adenosine (55, 56).
Inflammation consequently induces focal hypoxia in the 
inflamed tissue. Since inflammatory tissue damage involves 
non-specific injury to vasculature, disruption of blood circula-
tion in the tissue causes deprivation of nutrients and oxygen 
downstream, and the resulting tissue hypoxia may increase 
extracellular adenosine production (57, 58). In addition, cellular 
damage, another consequence of proinflammatory activities, can 
result in the release of a large amount of adenine nucleotides, 
such as ATP, ADP, AMP, and adenosine, into the extracellular 
space. A combination of adenine nucleotide release and CD39/
CD73 upregulation induces a robust accumulation of adenosine. 
Indeed, inflammation has been found to accompany an increase 
in extracellular adenosine levels (59–61). This hypoxia-induced 
metabolic switch favoring adenosine accumulation changes 
the course of inflammation. When inflammatory damage is 
excessive, the tissue will face an imminent danger, the loss of 
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function. Adenosine produced from the hypoxic and damaged 
tissue can stop proinflammatory activities and, instead, facilitate 
anti-inflammatory activities (58). Moreover, adenosine promotes 
angiogenesis, which is an ultimate solution to tissue hypoxia, and 
tissue remodeling (62, 63). Therefore, adenosine upregulation in 
the hypoxic tissue can serve as a negative feedback mechanism 
of inflammation, promoting a switch from propagation of proin-
flammatory response to resolution of inflammation.
An important factor in keeping inflammation under control 
is the induction of a metabolic switch favoring adenosine 
accumulation. Just as A2AR deficiency caused exaggeration of 
inflammation, CD39- or CD73-deficient mice provided further 
evidence for the importance of endogenous adenosine in control-
ling inflammation (64–69). Although the release of intracellular 
adenosine from damaged cells can also increase extracellular 
adenosine levels, exaggerated inflammation in the absence of 
CD39 or CD73 indicates the pathophysiological significance of 
the metabolic adenosine production at the outer membrane. The 
importance of CD73 enzymatic activity was confirmed using an 
inhibitor of nucleotidase activity. It is also interesting that Treg 
cells express both CD39 and CD73, and the produced adenosine 
serves as an immunoregulatory mechanism of Treg cells (70–72).
Such biological significance of ectonucleotidases implied the 
role in the suppression of antitumor immunity. Interestingly, 
CD73 expression has been observed in mouse tumor cell lines 
(73–75) and tumor cells from various cancer patients (76–83). 
Those tumor cells are likely to generate adenosine by themselves 
for protection from immune cells. Inhibition of CD73 can reduce 
tumor growth (75), and indeed the suppression of tumor growth 
was found to be immune response dependent (84). Neutralization 
of CD73 by antibodies reduced tumor growth and metastasis 
from the primary tumor (84, 85). The reduction in tumor growth 
was not observed in immunocompromised mice, suggesting an 
involvement of antitumor immunity. Since anti-CD73 antibody 
did not block tumor growth in A2AR-deficient mice (84), it is 
likely that adenosine produced from CD73-expressing tumor cells 
suppresses antitumor immune response in an A2AR-dependent 
fashion. Supporting this speculation, knockdown of CD73 in 
tumor cells reduced their growth in vivo and increased their sus-
ceptibility to antitumor immune cells (84, 86). Tumor growth is 
also retarded in CD73-deficient mice, suggesting that adenosine 
production from non-tumor host cells also contributes to the 
establishment of the immunosuppressive environment (67, 68).
CD39, in conjunction with CD73, can promote adenosine 
accumulation and thereby inhibit immune activities in tumors. 
Deletion of CD39 from vasculature or bone marrow-derived 
cells as well as administration of a CD39 inhibitor blocked tumor 
growth in a model of hepatic metastasis (87). In human cancer, 
CD39 expression was observed in tumor cells, tumor stroma, and 
infiltrated lymphocytes (88). Inhibition of CD39 on tumor cells 
can relieve coexisting immune effector cells from immunosup-
pression (88, 89). Taken together, tumors often upregulate the 
extracellular adenosine-producing mechanism. Therefore, CD39 
and CD73 are potential targets to block adenosine-dependent 
immunosuppression in tumors.
When mutated cells arise, immune cells may be able to rec-
ognize newly developed nascent tumor cells as abnormal and 
eliminate them (90). This immunosurveillance is considered to 
prevent cancer formation as shown by increased cancer incidence 
in immunocompromised mice that are lacking IFN-γ or perforin 
(91). Although most immune cells can exert a tumor-eliminating 
response, emergence of immune cells that produce anti-
inflammatory cytokines or have immunoregulatory functions 
will change the microenvironment into tumor-permissive one. 
Since adenosine suppresses cellular immunity and promotes the 
switch to a tolerant immune profile, an abundance of extracel-
lular adenosine may be detrimental to the prevention of cancer 
development. Consistent with this view, double transgenic mice 
expressing human papilloma virus type 16 E7 oncogene (E7) and 
A2AR were prone to spontaneous cancer development compared 
to E7-single transgenic mice. Thyroid specific coexpression 
of E7 and A2AR resulted in rapid development of thyroid 
carcinoma and lung metastasis of malignant thyroid cancer 
cells (92). Conversely, A2AR-deficient mice showed a reduced 
cancer incidence in 3-methylcholanthrene-induced chemical 
carcinogenesis (93). CD73-deficient mice were also resistant 
to 3-methylcholanthrene-induced carcinogenesis (68). CD73 
deficiency is preventive to spontaneous prostate cancer develop-
ment in TRAMP-transgenic mice (68). These studies suggest 
the significance of the adenosine system in cancer development, 
although the mechanism of cancer prevention needs further 
investigation.
NON-iMMUNe TARGeTS OF ADeNOSiNe 
iN CANCeR
As discussed above, immunosuppressive effects of extracellular 
adenosine provide tumors a protection from antitumor immunity. 
However, immune cells are not the only targets of the pro-tumor 
effect of adenosine. Some tumor cells have been found to express 
adenosine receptors, and adenosine may support tumor progres-
sion directly. In tumor cell culture in vitro, the addition of adeno-
sine to the culture enhanced tumor cell proliferation. Cotreatment 
with antagonists suggested that the effect was mediated by A2AR 
or other adenosine receptors (94, 95). Adenosine can also prevent 
apoptosis of tumor cells, and A2AR antagonist reversed this effect 
(95). As discussed above, some tumor cells express CD73 and are 
able to increase extracellular adenosine levels. Tumor cell-derived 
adenosine not only protects the tumor from immune cells but 
also autonomously enhances tumor growth. Downregulation of 
CD73 in siRNA-transduced tumor cells reduced cell proliferation 
in vitro as well as tumor growth in vivo (75, 96). APCP, an inhibitor 
of enzymatic activity of CD73, also inhibited CD73-expressing 
tumor cell proliferation and increased apoptosis (94, 96). In 
contrast, CD73 overexpression increased tumor cell proliferation 
and viability (96).
CD73 expression on human cancer cells may induce resistance 
to chemotherapy. In human breast cancer cells, higher CD73 
expression was associated with lower therapeutic response to 
anthracyclines (79). CD73 inhibitor sensitized the tumors to doxo-
rubicin. In chronic lymphocytic leukemia, cancer cells constitu-
tively express A2AR, and autonomous adenosine production with 
their own CD39/CD73 can result in A2AR-dependent prevention 
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of drug-induced apoptosis (78). The inhibition of CD73 activity 
in glioblastoma cells decreased tumor cell viability to vincristine 
by downregulating multidrug transporter protein 1 (MRP1) (80).
Moreover, adenosine and CD73 expression may play a role 
in metastasis of cancer cells. CD73 downregulation by antibody 
or siRNA reduced adhesion, invasion, and migration of CD73-
expressing tumor cells (75, 84). Conversely, CD73 overexpression 
increased adhesion and migration (97). When tumor cells were 
pretreated with anti-CD73 mAb before injection into mice, their 
extravasation and metastasis in  vivo were decreased compared 
to control tumor cells (85). Addition of adenosine to the tumor 
cell culture increases tumor cell adhesion and migration (97, 98). 
Since adenosine does not increase tumor cell migration in the 
absence of A2AR (98), the adenosine-A2AR system may promote 
tumor metastasis by, in addition to its suppressive effect on anti-
tumor immune response (29, 84, 99), directly activating tumor 
cell adhesion and migration. Although the pro-metastatic effect 
of CD73 may be mediated by adenosine production through its 
enzymatic activity, the non-enzymatic role of CD73 is also sug-
gested in tumor cell migration (85).
TiSSUe HYPOXiA AND 
iMMUNOSUPPReSSiON iN TUMORS
Thus, adenosine plays important roles in the establishment of 
an immunosuppressive tumor microenvironment and cancer 
progression. Adenosine is present in tumors at much higher 
levels than in normal tissues (18, 19). Tissue hypoxia seems to be 
crucial to the increase in intratumoral adenosine levels because 
reversal of tissue hypoxia by exposing tumor-bearing mice to 
hyperoxic atmosphere (60% oxygen) largely reduced tumor 
adenosine levels (100). Tumors are found to be hypoxic (101, 
102) probably because of high oxygen demand by proliferating 
cells and insufficient oxygen supply due to sluggish blood flow 
in the disorganized tumor vasculature. Tissues under hypoxic 
stress shift adenosine metabolism toward its accumulation in 
the extracellular space. On one hand, hypoxia induces CD39 and 
CD73 and increases catabolic adenosine production (53, 103). 
On the other hand, hypoxia downregulates adenosine kinase and 
thereby inhibits conversion of adenosine (55, 56).
Corresponding to the increase in adenosine levels, hypoxia 
is known to be immunosuppressive. When cultured at various 
degrees of hypoxic atmosphere (1–5% oxygen), T cells undergo 
an impaired T cell receptor-mediated activation process (104) and 
reduce proliferation, cytokine production, and cytotoxicity (16, 
105–108). T cell stimulation in mice breathing hypoxic atmosphere 
(10% oxygen) confirmed the impairment of T cell activation in vivo 
(16, 109). Consistent with the effects on T cells, hypoxia impairs the 
antigen-presenting function of dendritic cells and macrophages. 
Exposure of APCs to hypoxia downregulated both antigen uptake 
(110) and expression of MHC and costimulatory molecules (111, 
112), resulting in the inability to achieve full activation of T cells. 
Immunosuppressive effects of hypoxia further include inhibition of 
NK cell activity (113) and induction of immunosuppressive activity 
of MDSCs (114). Although hypoxia conducts various functional 
changes through adenosine receptor-dependent mechanisms 
(115–117), an  unidentified adenosine receptor-independent 
mechanism may also contribute to T cell suppression under 
hypoxia (16). While T cell proliferating activity is relatively resist-
ant to A2AR-mediated T cell suppression, hypoxia strongly reduces 
T cell proliferation in an A2AR-independent manner (16, 31).
Nonetheless, tissue hypoxia, at least in part, contributes to 
immunosuppression in the tumor microenvironment. Many 
anti-inflammatory molecules are present in tumors; hypoxia may 
be responsible for the upregulation of some, if not all, of them. 
Reversal of hypoxia by whole body exposure to hyperoxic atmos-
phere (60% oxygen) reduced intratumoral expression of TGF-β, 
CTLA-4, COX-2, and FoxP3 (100, 118). In the same study, levels 
of CD39, CD73, A2AR, and A2BR in tumors were also reduced in 
response to hyperoxia, suggesting oxygen-dependent regulation 
of adenosine signaling pathway. Consistent with these changes 
indicating a switch to a more immuno-permissive tumor micro-
environment, hyperoxia treatment inhibited tumor progression 
with an enhanced cellular immune response.
When deprived of oxygen, cells urgently need to prepare 
for the inevitable loss of oxidative energy production. To adapt 
to this dangerously stressful condition, cells quickly promote 
anaerobic energy production by glycolysis. A crucial molecule 
conducting this metabolic switch is HIF-1α, a transcriptional 
factor regulating glycolytic enzymes together with angiogenesis 
and erythropoiesis (119, 120). Tumor cells are known to utilize 
glycolysis even under aerobic conditions and satisfy their high 
energy demand with this all-out energy production. Therefore, it 
seems reasonable that increased HIF-1α levels in human cancers 
are positively correlated with the increased risk of mortality 
(121). While HIF-1α expression in tumors may indicate the pres-
ence of potentially immunosuppressive tissue hypoxia, HIF-1α 
may actively regulate immunosuppressive mechanisms. HIF-1α 
can mediate CD73 induction by hypoxia and promote adenosine-
dependent immunosuppression (53). HIF-1α may be inhibitory 
to T cell activation as indicated by attenuated T cell receptor 
signaling (104). Indeed, T cells lacking HIF-1α showed stronger 
effector functions (122,  123) and caused severe inflammation 
(124). Contrary to the T cell suppressive role of HIF-1α, however, 
deletion of HIF-1α in myeloid cells diminished inflammation 
(125, 126). Bactericidal activities of macrophages and neutrophils 
are impaired when they lack HIF-1α (127). Interestingly, HIF-
1α also positively regulates activity of MDSC, supporting their 
immunosuppressive activity, PD-L1 expression and conversion 
into tumor-associated macrophages (114, 128). These studies 
suggest that myeloid cells need HIF-1α for their activities, while 
HIF-1α may be inhibitory to T cell effector functions.
HIF-1α is also vital in controlling Treg cells, but its role is com-
plex. Initially, hypoxia was reported to upregulate FoxP3 in mouse 
and human T cells (129). The induction of Treg cells in hypoxic 
conditions was confirmed (130) and extended in the demonstra-
tion of decreased immunoregulatory activity of HIF-1α-deficient 
Treg cells (131). Contrary to the positive role of HIF-1α in Treg 
cell induction, functional differentiation of HIF-1α-deficient 
CD4+ T cells demonstrated an increase in FoxP3+ Treg cells and 
a reciprocal decrease of Th17 cells (132, 133). The preferential dif-
ferentiation into Treg cells in the absence of HIF-1 α was consistent 
with the reduced magnitude of inflammation in these animals. 
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Inflammation was rather enhanced when Treg cells overexpress 
HIF-1α due to the lack of von Hippel–Lindau tumor suppressor 
(VHL), which degrades HIF-1α protein in normoxic conditions 
(134). Such a proinflammatory phenotype of these mice corre-
sponded well with the reduction of FoxP3 and immunoregulatory 
activity. Similar changes were observed in Deltex1-deficient mice 
in which the lack of HIF-1α degradation led to its accumulation 
(135). In these studies, abundance of HIF-1α is considered to pro-
mote FoxP3 degradation leading to downregulation of Treg cells 
(133, 135). Nonetheless, even if roles of hypoxia and HIF-1α on 
Treg cell induction and immunregulatory activity are not clear, 
tumors contain a number of Treg cells. Another possibility for the 
increase of intratumoral Treg cell population is the active recruit-
ment of Treg cells from the outside of tumors. Indeed, hypoxia 
triggers induction of a chemokine, CCL28, which attracts Treg 
cells into tumor tissues (136).
TARGeTiNG THe HYPOXiA–ADeNOSiNe 
PATHwAY FOR iMMUNe CHeCKPOiNT 
THeRAPY
For immune cells, the battle against tumors is a war that has to be 
fought in the enemy’s home ground. Although hypoxic tissue is 
a harsh environment for every cell, it may be a more challenging 
condition for immune cells than for tumor cells, which are ready 
to utilize various kinds of energy sources very aggressively. Since 
tumor cells drain energy sources as much as possible, it is hard for 
immune cells to keep on fighting in this scorched battleground. In 
addition, the inside of tumor tissue is a very hostile environment 
filled with a number of traps that will try to discourage the antitu-
mor activity of immune cells. Many of such immunosuppressive 
activities are the use (abuse) of physiological immunoregulatory 
mechanisms that were originally intended to save vital organs 
from substantial inflammatory damage. Deceived by this 
false order, immune cells stop fighting tumor cells. As a result, 
immune cells, even highly activated immune effector cells that 
can recognize tumor-associated antigens, struggle mightily in 
the tumor. Hypoxia-inducible extracellular adenosine represents 
the physiological immunoregulatory molecules that are used to 
fortify tumors against immune system.
After adenosine-dependent tumor protection was first reported 
in 2006, extensive research on this pathway has revealed its sig-
nificance in cancer immunology and cancer biology. Hypoxia and 
adenosine not only directly inhibits immune cell functions but 
also triggers induction of various anti-inflammatory molecules as 
well as emergence of immunoregulatory cells such as Treg cells, 
MDSC, and M2-type macrophages. The latter may contribute 
FiGURe 1 | Pro-cancer activities of extracellular adenosine and therapeutic targets for improvement of cancer immunotherapy. Tissue hypoxia in 
tumors increases extracellular adenosine production through induction of CD39 and CD73. Produced adenosine transmits immunosuppressive signals through 
adenosine receptors on various immune cells. A2AR stimulation in effector T cells (Teff) blocks T cell receptor signaling and impairs effector functions including IFN-γ 
production and cytotoxicity. In antigen-presenting cells (APC), signals through A2AR and A2BR reduce Th1-type cytokine milieu and induce tolerogenic APC. 
Interaction of Teff with these APC will impair activation of cellular immune response against cancer cells. Adenosine enhances immunoregulatory activity of regulatory 
T cells (Treg). The qualitative and quantitative increase of Treg results in stronger inactivation of antitumor immune response. In addition, adenosine can promote 
proliferation, survival and metastatic activity of cancer cells. Suppression of adenosine pathway will be able to weaken the intensity of immunosuppression in tumor 
microenvironment and direct effect on cancer cells. Potential target molecules are adenosine receptors (A2AR and A2BR) and adenosine-producing enzymes (CD39 
and CD73). Oxygen supplementation can also decrease pro-cancer effects of adenosine as well as adenosine-independent immunosuppression by hypoxia.
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to establishing a long-lasting immunosuppressive environment 
in tumors. The pro-tumor effect of adenosine is not limited to 
immunosuppression, and it involves non-immunological pro-
tumor effects, which promote tumor cell proliferation, tumor 
cell survival, metastasis, and angiogenesis. Clinical data support 
the pro-tumor effects of the hypoxia–adenosine pathway. Many 
cancer cells express CD73, and CD73 expression is associated 
with poor prognosis of various cancers such as breast (79), 
ovarian (77, 83), prostate (81, 82), brain cancers (80), and leu-
kemia (76, 78). Resistance to chemotherapy has been reported in 
CD73-expressing cancers (78–80). An association with increased 
mortality has also been observed in cancers with poorly oxygen-
ated areas (102, 137, 138) and in cancers expressing HIF-1α at 
high levels (139, 140). Corresponding to the poor prognosis, 
hypoxic cancers are found to be refractory to radiotherapy and 
chemotherapy.
Inactivation of the hypoxia–adenosine pathway may be able 
to relieve antitumor immune effector cells from immunosup-
pressive signaling, convert an immunosuppressive tumor micro-
environment to a more immuno-permissive one, and reduce 
metastatic activity and resistance to chemotherapy and radio-
therapy (Figure 1). The pathway can be targeted in different steps. 
Antagonists of adenosine receptors block adenosine signaling 
and improve tumor regression (19, 21, 41). Reduction of extra-
cellular adenosine levels by CD73 inhibitor also improves tumor 
regression (141, 142). Improvement of tissue oxygenation status 
reduces adenosine levels and enhances immune cell activities as 
observed in mice breathing hyperoxic atmosphere (100, 118). 
When combined with therapeutic approaches that increase the 
number of antitumor cells, the anti-hypoxia–adenosine strategy 
may synergistically enhance efficacy by preventing inactivation of 
effector cells. Preclinical studies have shown further retardation 
of tumor growth and reduction of metastatic tumor nodules in 
combined treatments with adoptive immunotherapy (19, 86) 
or cancer vaccines (143). Interestingly, anti-hypoxia–adenosine 
therapy cooperates well with other immune checkpoint inhibi-
tors such as ani-CTLA-4 and anti-PD-1 mAbs (29, 34, 47, 144). 
The complexity of regulating antitumor immunity may limit 
success in treatments targeting a single mechanism. However, 
combined treatment with the anti-hypoxia–adenosine strategy 
may improve the clinical response to other immunotherapy as 
well as chemotherapy and radiotherapy.
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